181.
The prognosis of common mental disorders in adolescents: a 14-year prospective cohort study
by Patton, George C, Prof
The Lancet (British edition), 2014, Vol.383 (9926), p.1404-1411
182.
Myelodysplastic syndromes
by Adès, Lionel, MD
The Lancet (British edition), 2014, Vol.383 (9936), p.2239-2252
183.
Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-...
by Shigemori, Tsunehiko
Annals of surgical oncology, 2018, Vol.26 (3), p.876-883
185.
Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
by Clive, Amelia O
Thorax, 2014, Vol.69 (12), p.1098-1104
186.
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm,...
by Ladenstein, Ruth, Prof
The lancet oncology, 2017, Vol.18 (4), p.500-514
187.
Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma
by Ueberroth, Benjamin E
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2022
188.
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
by Walter, Steffen
Nature medicine, 2012, Vol.18 (8), p.1254-1261
189.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
by Robert, Caroline, Prof
The lancet oncology, 2019, Vol.20 (9), p.1239-1251
190.
Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer
by Li, Zhonghu
Cancer letters, 2018, Vol.432, p.237-250
191.
227 Surgical Management of Ewing's Sarcoma of the Spine: Survival and Local Control Outcomes
by Rhines, Laurence D
Neurosurgery, 2017, Vol.64 (CN_suppl_1), p.262-262
192.
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phas...
by Bridgewater, John A
The lancet oncology, 2020, Vol.21 (3), p.398-411
193.
Stromal gene expression predicts clinical outcome in breast cancer
by Park, Morag
Nature medicine, 2008, Vol.14 (5), p.518-527
194.
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
by McArthur, Grant A, Prof
The lancet oncology, 2014, Vol.15 (3), p.323-332
195.
Stromal biology and therapy in pancreatic cancer
by Neesse, Albrecht
Gut, 2011, Vol.60 (6), p.861-868
196.
Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010
by Davies, Helen E
Thorax, 2010, Vol.65 (Suppl 2), p.ii41-ii53
197.
Consensus on biomarkers for neuroendocrine tumour disease
by Oberg, Kjell, Prof
The lancet oncology, 2015, Vol.16 (9), p.e435-e446
198.
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
by Burger, Jan A, Dr
The lancet oncology, 2014, Vol.15 (10), p.1090-1099
199.
Combination of novel biomarkers using liquid biopsy and imaging techniques as a more accurate tool for early detection of exocrine pancreatic cancer in high-risk populations
by Earl, J
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2022, Vol.22 (3), p.e1-e2
200.
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
by Kim, Seok Jin, Prof
The lancet oncology, 2016, Vol.17 (3), p.389-400
